Herrinton et al., in a cohort of patients with autoimmune disease, including RA, found that the risk of ILD was not increased in patients with exposure to anti-TNF therapy versus exposure to non-biologic disease-modifying anti-rheumatic drugs. Here, TNF is linked to autoimmune disease.